N-(5-carbamoylpyridin-2-yl)-N-cyclopropyl-3-(4-(methylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-5-carboxamide | 1610611-44-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(5-carbamoylpyridin-2-yl)-N-cyclopropyl-3-(4-(methylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-5-carboxamide
• 英文别名: N-(5-carbamoylpyridin-2-yl)-N-cyclopropyl-3-[4-(methylcarbamoyl)phenyl]pyrazolo[1,5-a]pyridine-5-carboxamide
• CAS: 1610611-44-3
• 化学式: C₂₅H₂₂N₆O₃
• 分子量: 454.488
• InChiKey: OSWSESLZUZQSOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-(N-cyclopropyl-3-(4-(methylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-5-carboxamido)nicotinic acid 在 氯化铵 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以35%的产率得到N-(5-carbamoylpyridin-2-yl)-N-cyclopropyl-3-(4-(methylcarbamoyl)phenyl)pyrazolo[1,5-a]pyridine-5-carboxamide
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  [FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES PARASITAIRES

  摘要：

  本发明提供了化合物的公式I：[在此插入公式]或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物以及使用这种化合物用于治疗、预防、抑制、改善或根除由疟原虫引起的疾病的病理学和/或症状学的方法，例如疟疾。

  公开号：

  WO2014078802A1

文献信息

• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：CHATTERJEE Arnab Kumar

  公开号：US20150344471A1

  公开（公告）日：2015-12-03

  The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

  本发明提供式I的化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供包含这种化合物的制药组合物以及使用这种化合物治疗、预防、抑制、改善或消除由疟原虫等引起的疾病的病理学和/或症状学的方法。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS
  申请人：Novartis AG

  公开号：US20190030009A1

  公开（公告）日：2019-01-31

  The invention relates to a method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of cryptosporidiosis by administering a therapeutic agent which antagonizes or modulates the activity of phosphatidylinositol-4-OH kinase (PI4K), a lipid kinase of the cryptosporidium protozoa. In one embodiment, the therapeutic agent is a pyrazolo[1,5-a]pyridine compound of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein.
• US9556169B2
  申请人：——

  公开号：US9556169B2

  公开（公告）日：2017-01-31
• US9926314B2
  申请人：——

  公开号：US9926314B2

  公开（公告）日：2018-03-27
• [EN] COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR LE TRAITEMENT DE LA CRYPTOSPORIDIOSE
  申请人：NOVARTIS AG

  公开号：WO2017125898A1

  公开（公告）日：2017-07-27

  The invention relates to a method for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of cryptosporidiosis by administering a therapeutic agent which antagonizes or modulates the activity of phosphatidylinositol- 4-OH kinase (PI4K), a lipid kinase of the cryptosporidium protozoa. In one embodiment, the therapeutic agent is a pyrazolo[1,5-a]pyridine compound of Formula (I), or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein.